GREY:ICOTF - Post by User
Comment by
eddy0505on Aug 07, 2018 6:07pm
156 Views
Post# 28424065
RE:Preliminary short form prospectus filing
RE:Preliminary short form prospectus filingFrom today’s filed prospectus.... they should get financing or partnership deal I believe..
market for antifungal in billions & growing..
Cost of advancing trials..from today’s filing Aug 7th..
iCo has completed Phase I trials of the Oral Amp B Delivery System. Assuming initiation of later staged trials in 2018, we could expect filing for drug approval as early as 2021. We currently estimate that costs for a 90 patient Phase II study would be approximately US$2,000,000 and subsequent Phase III anti-fungal trials would be approximately US$5,000,000 to US$10,000,000 depending on whether one or two pivotal studies is required. Phase III studies would likely involve 100-150 patients per treatment arm. VL trials may be cheaper if conducted in a developing world setting. Phase III may involve roughly 600 patients. The Company intends to seek additional grant monies to offset clinical study costs. Groups sponsoring such work include Drugs for Neglected Diseases Initiative, the Bill and Melinda Gates Foundation and a number of other government sponsored initiatives.